Further to DrugAlert volume 803, HPS Pharmacies wish to advise that Eli Lilly is continuing to experience a supply interruption for Trulicity® as follows:
Dulaglutide (rch) 1.5 mg/0.5 mL
Eli Lilly has revised their expected return date to end-March 2023. An internationally registered brand of dulaglutide (rch) 1.5 mg/0.5 mL pens has been approved for supply under Section 19A of the Therapeutic Goods Act 1989.
For comprehensive information and updates, please go to the Trulicity (dulaglutide) shortage page available on the Therapeutic Goods Administration (TGA) website.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Eli Lilly on 1800 454 559 or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates